Drug & intervention

lenvatinib

RxCUI 1603296

Clinical trials64
Recruiting6
Related conditions20
Synonyms1

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…

Clinical trials

40 shown
Cryoablation Combined With Lenvatinib Plus QL1706 (Iparomlimab/Tuvonralimab) in Patients With Advanced Intrahepatic CholangiocarcinomaNCT07070700 · 2025-08-20
RECRUITING
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)NCT06858813 · 2025-04-14
RECRUITING
Hepatic Arterial Infusion Chemotherapy (HAIC) Combined With Durvalumab and Lenvatinib in Patients With Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma: a Phase 2 Study(HAIC-quad Trial)NCT06859684 · 2025-03-01
RECRUITING
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)NCT05319730 · 2023-05-16
RECRUITING
GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid TumorsNCT04977453 · 2021-08-02
RECRUITING
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor TypesNCT04300556 · 2020-08-06
RECRUITING
Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic CholangiocarcinomaNCT07691515 · 2026-07-01
NOT_YET_RECRUITING
A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular CarcinomaNCT07131501 · 2025-08-11
NOT_YET_RECRUITING
HIM Typing Guides the Treatment of Advanced First-Line Triple-Negative Breast CancerNCT06849492 · 2025-04-01
NOT_YET_RECRUITING
AMG510 (sotorasib) Plus Lenvatinib As Second-line Treatment in Patients with KRASG12C Mutant, Metastatic NSCLCNCT06068153 · 2025-03-01
WITHDRAWN
Adebrelimab Combined with Irinotecan Liposomes, 5-FU, CF ± Lenvatinib As First-line Treatment for Advanced ICCNCT06648525 · 2024-10-01
NOT_YET_RECRUITING
OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older AdultsNCT05949424 · 2024-05-01
UNKNOWN
Study of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural MesotheliomaNCT06318286 · 2024-03-13
ACTIVE_NOT_RECRUITING
A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast CancerNCT06110793 · 2023-12-29
ACTIVE_NOT_RECRUITING
The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breast Cancer: a Phase Ib/IIa Clinical Trial.NCT06140576 · 2023-11-30
NOT_YET_RECRUITING
Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC PatientsNCT06028633 · 2023-10-01
NOT_YET_RECRUITING
Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)NCT06036836 · 2023-09-29
COMPLETED
Study of Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-stage Small Cell Lung CancerNCT05384015 · 2022-11-07
ACTIVE_NOT_RECRUITING
A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)NCT05342636 · 2022-07-27
COMPLETED
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension StudyNCT05899049 · 2022-07-27
ACTIVE_NOT_RECRUITING
Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR MutationsNCT05258279 · 2022-07-01
COMPLETED
KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 AgentNCT05001724 · 2021-10-28
TERMINATED
A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC PatientsNCT05078931 · 2021-10-27
ACTIVE_NOT_RECRUITING
Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLCNCT04989322 · 2021-10-05
UNKNOWN
MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)NCT05007106 · 2021-09-16
COMPLETED
Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)NCT04938817 · 2021-08-19
ACTIVE_NOT_RECRUITING
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).NCT04949256 · 2021-07-28
TERMINATED
Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)NCT04924101 · 2021-07-15
COMPLETED
Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate CancerNCT04848337 · 2021-05-25
ACTIVE_NOT_RECRUITING
Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02)NCT04700072 · 2021-05-03
COMPLETED
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)NCT04736706 · 2021-04-14
ACTIVE_NOT_RECRUITING
Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)NCT04776148 · 2021-03-29
COMPLETED
Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)NCT04740307 · 2021-03-16
COMPLETED
Pembrolizumab Plus Lenvatinib In Second Line and Third Line Malignant Pleural mesotheLioma PatientsNCT04287829 · 2021-03-01
ACTIVE_NOT_RECRUITING
Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)NCT04704219 · 2021-02-23
COMPLETED
Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)NCT04626518 · 2020-12-17
COMPLETED
Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)NCT04626479 · 2020-12-16
COMPLETED
Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)NCT04428151 · 2020-08-06
COMPLETED
A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell CarcinomaNCT04522323 · 2020-08-05
ACTIVE_NOT_RECRUITING
Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advanced Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)-China Extension StudyNCT04889118 · 2020-07-14
COMPLETED

Conditions being studied

Carcinoma, Renal Cell4Intrahepatic Cholangiocarcinoma (Icc)4Melanoma3Non-small Cell Lung Cancer3Advanced Non-Small Cell Lung Cancer2Carcinoma, Hepatocellular2EGFR Activating Mutation2Endometrial Neoplasms2Hepatocellular Carcinoma2Malignant Melanoma2Nonsquamous Non-small Cell Lung Cancer2NSCLC2Renal Cell Carcinoma2Solid Tumor2Squamous Cell Carcinoma of Head and Neck2Triple Negative Breast Cancer2Urothelial Carcinoma2Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive1Advanced Cancer1Advanced Hepatocellular Carcinoma1

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.